medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2003, Number 1

<< Back Next >>

Ann Hepatol 2003; 2 (1)

Terbinafine hepatotoxicity. A case report and review of literature

Zapata GAJ, Casillas RA, Bosques PF

Language: English
References: 17
Page: 47-51
PDF size: 140.81 Kb.


Text Extraction

We report a 53-year old Mexican female who developed liver dysfunction following a seven-day course of treatment with terbinafine for onychomycosis. She presented with jaundice and abdominal pain. Her serum bilirubin levels showed a peak value of 23.2 mg/dL seven weeks after discontinuing the medication. Infectious causes (hepatitis viruses A, B and C) were excluded. Imaging studies of the abdomen did not reveal any abnormalities. Serum iron and ceruloplasmin levels were normal. Autoantibodies were negative. A liver biopsy revealed necrosis and mononuclear infiltration of the parenchyma, mainly along the sinusoids and surrounding the portal spaces and biliary ducts. Eosinophil infiltration of the portal spaces was also noted. Treatment with ursodeoxycholic acid and ademethionine was started. Her liver tests normalized in the sixth months after stopping terbinafine.


REFERENCES

  1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-5.

  2. Lewis JH, Zimmerman HJ. Drug-induced liver disease. Med Clin N Am 1989; 73: 775-92.

  3. Pillans PI. Drug associated hepatic reactions in New Zealand: 21 years experience. N Z Med J 1996; 109: 315-9.

  4. Ostapowicz G, Fontana RJ, Larson AM, et al. Etiology and outcome of acute liver failure in the USA: preliminary results of a prospective multi-center study. Hepatology 1999; 30: 221A.

  5. Fernandes NF, Geller SA, Fong T. Terbinafine hepatotoxicity : Case report and review of the literature. Am J Gastroenterol 1998; 93: 459-60.

  6. Zimmerman HJ. Hepatotoxicity. 2nd ed. Philadelphia: Lippincott, Williams & Wilkins, 1999.

  7. Benichou C. International consensus meeting: criteria of drug-induced liver disorders. J Hepatol 1990; 11: 272-6.

  8. Aithal GP, Rawlilns MD, Day CP. Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. J Hepatol 2000; 33: 949-52.

  9. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1331-6.

  10. Lucena MA, Camargo R, Andrade RJ, et al. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001; 33: 123-30.

  11. Maria VAJ, Victorino RMM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26: 664-9.

  12. Irey NB. Tissue reactions to drugs. Am J Pathol 1976; 82: 617-48.

  13. Irey NB. When is a disease drug-induced? In: Riddell RH, editor. Pathology of drug-induced and toxic diseases. New York: Churchill Livingstone, 1982; 1-18.

  14. Physicians’ Desk Reference. 55th ed. Medical Economics, 2001.

  15. Farrell GC. Drug-induced liver disease. Edinburgh: Churchill Livingstone, 1994.

  16. Stricker BHC. Drug-induced hepatic injury. 2nd ed. Amsterdam: Elsevier, 1992.

  17. Zimmerman HJ, Ishak KG. Hepatic injury due to drugs and toxins. In: MacSween RMN, Burt AD, Portmann BC, Ishak KG, Scheuer PJ, Anthony PP, eds. Pathology of the liver. London,




2020     |     www.medigraphic.com